Abstract: The temperature-sensitive triblock copolymer poly-(D, L-lactic acid-co-glycolic acid) (PLGA)-polyethylene glycol (PEG)-PLGA (PLGA-PEG-PLGA) is an FDA-approved material that has the ability to provide a sustained release of drugs and/or proteins. Platelet-rich fibrin(PRF)is second generation platelet concentration that contains growth factors such as transforming growth factor-1 (TGF-1), platelet derived growth factor-AB (PDGF-AB), and insulin-like growth factor-I (IGF-I). These growth factors affect the migration and proliferation of diverse cell types, including endothelial cells, smooth muscle cells, and osteoblast-like cells. This study sought to combine the hydrogel into scaffolds in order to serve as a sustained release system for PRF-derived growth factors. Poly (lactic-co-glycolic) acid (PLGA) and nano-hydroxyapatite (nHA) were used to prepare the hydrogel-containing scaffolds with the PRF-derived growth factors. We then investigated the effects of the hydrogel on modulating the activity of osteoblasts in vitro. We indicated that the hydrogel (Gel) was well-distributed in the inner surface of scaffolds, which themselves exhibited relatively interconnected pores with uniform sizes. The addition of the hydrogel didn't affect their inherently high porosity. In vitro release tests indicated that the system containing nHA/PLGA/Gel/PRF provided for a slow and sustained release of PRF-derived growth factors. The results from our in vitro studies indicated that the MG63 cells cultured with both scaffold media extracts did not appear to have cytotoxic responses, and the nHA/PLGA/Gel/PRF system could improve the adhesion and proliferation of MG63 cells when compared to controls (p < 0.05). This in vitro evaluation suggests that the hydrogel-scaffold system is suitable as a model for bone tissue engineering, and that it allows for the sustained release of growth factors to improve bone reconstruction.
Introduction
Bone defects have a variety of etiologies, including tumors, trauma, congenital malformations, and osteomyelitis. Such defects can significantly reduce patients' quality of life and frequently pose major challenges during reconstructive surgery. Possible treatments for bone defects include autografts and allografts have their limitations, include the need for a second site of surgery, limited availability of appropriate tissue, and/or risk of immunogenicity 1) . With these adverse consequences, tissue engineering using artificial bone grafts is a valid and exciting alternative to traditional methods. These artificial grafts are comprised mainly of cells, select bioactive agents, and biomaterial scaffolds 2) . Scaffolds are key graft components, as they provide stable support for cell adhesion, growth, and differentiation. Ideal scaffolds must allow for proper cell adhesion and growth in combination with the necessary porosity, biocompatibility, biodegradability, and mechanical strength that are required for use in biological systems 3) . Poly (lactic-co-glycolic acid) (PLGA) was approved for use by the Food and Drug Administration (FDA) as a popular scaffold, o wi n g t o i t s a d j u s t a b l e d e gr a d a t i o n r a t e a n d g o o d biocompatibility 4) . However, its poor hydrophilicity and lacking of cell anchorage sites has been shown to impede cell attachment and penetration of the scaffold 5) . Hydroxyapatite (HA) is similar to calcium apatite, a naturally occurring bone mineral. It is relatively easy to identify in cells or biomacromolecules, and it has the potential to improve the bioactivity, biocompatibility, and bioavailability of scaffolds. Moreover, the release of calcium and phosphorus ions during the degradation of HA may be involved in the formation of new bone. Given these advantages, a combination of PLGA with nano-hydroxyapatite (nHA/PLGA) might produce a material with high porosity and the ability to control scaffold pore size to better mimic natural bone structures 6) . Another method to improve the osteogenic ability of artificial scaffolds is the addition of growth factors. Platelet-rich fibrin (PRF)was first described by Choukroun et al., as a second generation platelet concentrate with a natural and progressive polymerization occurring during centrifugation without thrombin or calcium chloride 7) . Past work has shown that PRF concentrates almost all the growth factors that are stored in the -granules of platelets, including transforming growth factor-1 (TGF-1), platelet derived growth factor-AB (PDGF-AB), and insulin-like growth factor-I (IGF-I) 11) . These growth factors have been identified as key players in the process of tissue remodeling. Currently, PRF is widely used in the treatment of cartilage defects 9) , soft tissue defects 10, 13) , and bone defects 11, 12) . However, its poor mechanical strength has limited its application. To further restrict its practical application, PRF must be used immediately after preparation and the growth factor release occurred for a total duration of about 14 days 14) , which is too short to improve the bone reconstruction process. Therefore, a suitable method to extract the PRF-derived growth factors is required for their further application to biomaterials. Moreover, a suitable method to improve the mechanical strength of PRF as well as an efficient delivery and release system are also required for their future use in bone tissue engineering. Lyophilization is a widely used technique to improve the long-term storage stability of proteins and platelets 17) . However, neither the growth factors in lyophilized PRF nor the biomaterial application of lyophilized PRF has been reported.
The temperature-sensitive triblock copolymer poly-(D, L-lactic acid-co-glycolic acid) (PLGA)-polyethylene glycol (PEG)-PLGA (PLGA-PEG-PLGA) was first reported by Zentner 15) and was later improved upon by Qiao 16) . This copolymer exhibits a reversible sol-gel transition that can form physically cross-linked hydrogel without the use of a cross-linking agent. This cross-linking can occur over a wide range of temperatures, including those that are physiologically relevant (37 o C). Moreover, these copolymers can provide the sustained release of drugs or proteins from one to four weeks 15, 16) . With such advantages, PLGA-PEG-PLGA hydrogel has become increasingly attractive as a useful candidate for an injectable, drug delivery system. As such, its safety profile has been investigated thoroughly via FDA-prescribed tests 15) . However, its application for use in bone defects has been limited due to its poor mechanical strength.
Collectively, it is feasible to design an ideal delivery system that combines PLGA-PEG-PLGA hydrogel with nHA/PLGA scaffold, these two components would theoretically solve the problem of poor mechanical strength and the grow factors in hydrogel can improve the bioactivity of scaffold.
The aims of the present study were two-fold: First, to investigate the feasibility of introducing a PLGA-PEG-PLGA hydrogel into a PLGA/nHA scaffold to obtain a controlled and sustained-release system, second, to find a way to extract PRFderived growth factors and combine them into the hydrogel, and further to obtain a novel biomaterial for bone tissue engineering.
We then evaluated the morphological and the release rate of the composite scaffold. Finally, we evaluated the cytotoxicity and biological capabilities of the composite scaffold by culturing MG63 cells with them.
Materials and Methods
The examination was allowed by the Ethics Committee of Jilin University in Jilin province in China.
Materials
P olyeth ylene glyco l (P EG 1 000 ) an d stan nous 2 -ethylhexanoate were both purchased from Sigma (Saint Louis, USA), while DL -lactide (LA) and glycolide (GA) were obtained from Purac ( Gorinchem, Netherlands). All chemicals were analytical grade and did not require further purification. PLGA 
Preparation of PLGA-PEG-PLGA hydrogel and nHA/PLGA Scaffold
PLGA-PEG-PLGA triblock copolymer was synthesized by using a ring-opening method described by Qiao M et al. 16) . Briefly, polymerization from LA and GA [LA:GA = 3:1, PEG: PLGA = 3:7] , PEG (PEG1000:PEG1500 = 1:1). Stannous 2-ethylhexanoate was used as the initiator.
A 3-D porous scaffold of nHA/ PLGA was fabricated using the solvent casting/particulate leaching method 6) . Briefly, sucrose particles were mixed into a solution of nHA/PLGA with mass ratio of 6:1 (w/w). The porous scaffolds were sterilized with 25 KGy Co 60 radiation.
Preparation of Lyophilized PRF and Concentration of Growth
Factors Approximately 5 ml of venous blood was obtained from ten healthy, nonsmoker volunteers (female, age range: 23 to 28 years). The volunteers provided oral informed consent and the study was . This PRF clot was removed from the tube and then frozen at -80°C for 30min before being freeze dried overnight at -51 °C.
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To harvest the growth factors present in the PRF clot, we pulverized the lyophilized PRF with a mortar and pestle and then immersed it in 5ml of sterile PBS. The PBS was collected every day and fresh PBS was added into the tube. This process occurred for a total of 21 d. The levels of PDGF-AB, TGF-1 and IGF-I were assayed using a commercially available enzyme-linked immunosorbent assay kit from R&D (Minneapolis, MN, USA) and following the manufacturer's protocol, the wavelength for ELISA measurement was 450nm. All assays were performed in triplicate.
In order to concentrate the indicated growth factors, we put the ground, lyophilized PRF into a centrifuge tube containing sterile PBS with concentration of two pieces of ground, lyophilized PRF clot/ml PBS and the tube was placed in an incubator at 37°C for 48 h , the concentrated solution was sterile-filtered through 0.2 m syringe filters.
Preparation and Characterization of Composite Scaffolds
The PLGA-PEG-PLGA hydrogel was dissolved in the aforementioned solution containing concentrated growth factors To determine the pore architecture of the composite scaffolds and the hydrogel structure contained on the inner surface of the scaffolds, the samples were cut from the middle. They were then placed on metal stubs and sputter coated with gold before examination using Scanning Electron Microscopy (SEM, XL30ESEM-FEG, FEL, Netherlands). 200 pores of each scaffold were measured for characterizing the pore size. The control sample used was the nHA/PLGA scaffold without the hydrogel.
Growth Factor Release
The composite scaffolds were incubated at 37 o C in 10 ml PBS for 12 weeks (pH 7.4). The samples were centrifuged for 5 min at 3000 rpm to ensure that the entire scaffold was immersed into the buffer. The buffer was changed weekly with fresh PBS.
The release of PDGF-AB, TGF-1, and IGF-I from the composite scaffolds was measured using commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA). All assays were performed in duplicate.
Cell toxicity, Adhesion and Proliferation
Human osteosarcoma MG63 cells were cultured at 37 o C in a Dulbecco's modified Eagle's medium (DMEM, HyClone, Logan, UT) supplemented with 10 % fetal bovine serum (FBS, HyClone, Logan, UT) and 1% penicillin/streptomycin (GIBCO, Grand Island, NY). They were then housed in an incubator with a humidified environment containing 5 % CO 2 .
The MG63 cells were either cultured on nHA/PLGA /hydrogel with growth factors (nHA/PLGA/Gel/PRF) or on nHA/PLGA / hydrogel without growth factors (nHA/PLGA/Gel). Both conditions were cultured for up to 6 h and at a seeding density of
1×10
4 cells/ml. Post-incubation, samples in both conditions were washed with PBS, fixed in 2.5% glutaraldehyde for one night at 4°C
, and dehydrated with a series of ethanol concentrations (10, 30, 50, 70, 90 and 100%) every 30min. Samples were then dried under vacuum conditions at room temperature and gold sputter coated before being examined by SEM.
A commercially available Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan) was used to test the cell toxicity and proliferation of MG63 cells incubated with either nHA/PLGA/ Gel/PRF or nHA/PLGA/Gel extracts. Both scaffolds were immersed in the aforementioned culture media and culture media samples were extracted at the end of the first, third, and fifth days.
Samples were stored at -80 °C before the proliferation test. Prior to testing, extracts were sterile-filtered through 0.2 m syringe filters. Pure culture media was used as a comparable control group.
MG63 cells were seeded in 96-well cell culture plates at a density of 3×10 4 cells/ml of medium in each well and incubated for 24 h. Then, the medium was replaced with either 100 l of culture medium that had been extracted after one day of incubation or pure culture medium and incubated for an additional 48h. This media was then replaced with culture media that had been extracted after 3 days or pure culture media for 48 h. This same procedure was replicated for media obtained after five days of incubation. An additional 10 l of CCK-8 solution was added to each well at the end of each incubation time and the plates were incubated for 1h at 37 °C. The absorbance of the samples was then measured by enzyme-linked immunosorbent assay microplate reader at a wavelength of 450 nm. Osteoblast viability was directly related to the measured optical density (OD).
Statistical Analyses
All data are expressed as mean ± SD. Statistical differences
were assessed by either a one-way analysis of variance (ANOVA) or Student's t-test. Statistical significance was defined as p < 0.05.
Results

Composite Scaffolds Characterization
The microstructure of the three-dimensional (3-D) porous scaffold of nHA/PLGA fabricated is shown in Fig. 1 (a, b) . Our results indicated that the scaffold contains irregular pores that are interconnected, pore diameter was approximately 150-270 m. The microstructure of the nHA/PLGA/Gel is shown in Fig. 1 (c- f). Our results showed that the hydrogel was successfully entered and well-distributed in the pores of the scaffold, the pores were not blocked by the hydrogel, and the composite scaffold still contained interconnected and irregular pores. The pore diameter was approximately 70-160 m.
Growth Factor Analysis of Ground, Lyophilized PRF
The released amounts of IGF-I(a),TGF-1(b) and PDGF-AB(c) from ground, lyophilized PRF in PBS solution are shown in Fig. 2 . It showed that there was a significantly large burst of growth factor release from ground, lyophilized PRF during the first 24 h. This was followed by a quick reduction over the next two days, and a slow, more consistent release from days 3 through 
Release Rate of growth factors in vitro
The cumulative release ratio of IGF-I (a), TGF-1 (b) and PDGF-AB (c) from nHA/PLGA/Gel/PRF is shown in Fig. 3 . The cumulative release ratio of IGF-I (a),TGF-1 (b) and PDGF-AB (c) in the first week is 34.2 %±4.2%, 36.2%±4.3% and 32.9%±3.1%, respectively. The cumulative release ratio of IGF-I (a),TGF-1 (b), and PDGF-AB (c) over four weeks is 66.29%±4.2%, 66.8%±4.4%, and 64.5%±4.2%, respectively. Our results showed that there was a slightly higher release rate in the first four weeks and then it reaching a liner rate of release rate.
Cellular Toxicity, Adhesion and Proliferation
As was shown in Fig 4. , when MG63 cells were cultured with scaffold extract mediums from the first day, there were no statistically significant differences in the OD value when compared to controls. When cultured with mediums from both the third and fifth days, OD values were attained statistically increased levels of the nHA/PLGA /Gel/PRF scaffold group compared to nHA/ PLGA /Gel scaffold and control groups. It indicated that the scaffolds did not have cytotoxic responses. And the nHA/PLGA/ Gel/PRF scaffold can stimulate osteoblast-like cellular proliferation during the early stages of bone reconstruction (*p < 0.05, n = 6).
The adhesion of MG63 cells to the nHA/PLGA /Gel scaffold (a-b) and nHA/PLGA/Gel/PRF scaffold (c-d) is shown in Fig.5 .
The MG63 cells appeared in a classic, spindle cell pattern. We found that the morphology and adhesion were better in the nHA/ PLGA/Gel/PRF scaffold. As shown in Fig. 5 (c-d) , it is surprising that the cell pseudopods protruded into the scaffold and the hydrogel simultaneously. This result could indicate that a hydrogel with grow factors could stimulate cellular adhesion when they come into contact with it during the early stages of bone reconstruction.
Discussion
PLGA/PEG/PLGA hydrogel was first introduced into tissueengineering scaffold materials as a delivery and sustained-release system. The combination of the hydrogel and a scaffold loaded with growth factors has been shown to be suitable for bone tissue engineering. The hydrogel was well-distributed in the scaffold and the scaffolds showed relatively uniform pore sizes with interconnected pores. The average pore diameter of nHA/PLGA/ Gel is a suitable range for cell and tissue penetration 18) . Lyophilization is a primary method for the storage of platelets to be used for wound repair 15, 19, 20) . The lyophilized PRF-derived growth factors were first extracted and introduced into sustainedrelease system and applied in tissue-engineering scaffold materials. The sustained-release of growth factors from nHA/PLGA/Gel/PRF scaffold is suitable for the bone tissue reconstruction process. The cellular adhesion and proliferation tests indicated that the nHA/ PLGA/Gel/PRF scaffold can induce osteoblast-like cellular adhesion and proliferation when they come into contact with it during the early stages of bone reconstruction. These results are likely due to the PRF-derived growth factors that were released from the nHA/PLGA /Gel/PRF scaffold.
PRF can be thought of as a cytokine bank that contains roughly all of the cytokines in the platelets 8) . Importantly, the growth factors obtained from PRF may not only have their own specific action on tissues, but may also interact with other growth factors. However, future research will be needed to examine these possible interactions and their subsequent effects.
These results suggest possibility of hydrogel/scaffold composite can be use to loading peptides and proteins, especially with sensitive proteins and drugs. Moreover, these results suggest the possibility of hydrogel-containing cells that can be distributed to the inner surface of the scaffold. Collectively, our work has shown that sustained-release growth factors from a hydrogel/ scaffold system may be a promising therapeutic agent for local application in bone tissue engineering.
